[96a5a0]: / output / allTrials / identified / NCT00212082_identified.json

Download this file

715 lines (715 with data), 30.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
{
"info": {
"nct_id": "NCT00212082",
"official_title": "Gene Expression Profiles of Breast Cancer Treated With Sequential Adriamycin and Docetaxel in Relation to Tumor Responses",
"inclusion_criteria": "* Female, age > 18 years.\n* Histologic or cytologic diagnosis of breast carcinoma.\n* Stage II to IV breast cancer with measurable primary breast tumor, defined as palpable tumor with both diameters 2.0cm or greater as measured by caliper.\n* Patients must not have received prior chemotherapy or hormonal therapy for the treatment of breast cancer.\n* Karnofsky performance status of 70 or higher.\n* Estimated life expectancy of at least 12 weeks.\n* Adequate organ function including the following:\n\n - Bone marrow: White blood cells (WBC) >= 3.5 x 109/L Absolute neutrophil (segmented and bands) count (ANC) >= 1.5 x 109/L Platelets >= 100 x 109/L Haemoglobin >= 9g/dL\n\n - Hepatic: Bilirubin <= 1.5 x upper limit of normal (ULN), ALT or AST <= 2.5x ULN, (or <=5 X with liver metastases) Alkaline phosphatase <= 2.5x ULN.\n\n - Renal: creatinine <= 1.5x ULN\n * Cardiac:\n * Adequate cardiac function\n* Signed informed consent from patient or legal representative.\n* Patients with reproductive potential must use an approved contraceptive method if appropriate (eg, intrauterine device, birth control pills, or barrier device) during and for three months after the study. Females with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Prior treatment for locally advanced or metastatic breast cancer.\n* Treatment within the last 30 days with any investigational drug.\n* Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.\n* Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.\n* Pregnancy.\n* Breast feeding.\n* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.\n* Poorly controlled diabetes mellitus.\n* Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.\n* Symptomatic brain metastasis.\n* History of significant neurological or mental disorder, including seizures or dementia.\n* Peripheral neuropathy of >= CTC grade 2.\n* History of hypersensitivity to drugs formulated in Tween 80, the vehicle used for commercial docetaxel formulations.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Female, age > 18 years.",
"criterions": [
{
"exact_snippets": "Female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "female"
}
]
},
{
"exact_snippets": "age > 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Histologic or cytologic diagnosis of breast carcinoma.",
"criterions": [
{
"exact_snippets": "Histologic or cytologic diagnosis of breast carcinoma",
"criterion": "breast carcinoma",
"requirements": [
{
"requirement_type": "diagnosis method",
"expected_value": [
"histologic",
"cytologic"
]
}
]
}
]
},
{
"line": "* Stage II to IV breast cancer with measurable primary breast tumor, defined as palpable tumor with both diameters 2.0cm or greater as measured by caliper.",
"criterions": [
{
"exact_snippets": "Stage II to IV breast cancer",
"criterion": "breast cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "N/A"
},
{
"operator": "<=",
"value": 4,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "measurable primary breast tumor",
"criterion": "primary breast tumor measurability",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": true
}
]
},
{
"exact_snippets": "palpable tumor",
"criterion": "tumor palpability",
"requirements": [
{
"requirement_type": "palpability",
"expected_value": true
}
]
},
{
"exact_snippets": "both diameters 2.0cm or greater as measured by caliper",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2.0,
"unit": "cm"
}
]
}
}
]
}
]
},
{
"line": "* Patients must not have received prior chemotherapy or hormonal therapy for the treatment of breast cancer.",
"criterions": [
{
"exact_snippets": "Patients must not have received prior chemotherapy ... for the treatment of breast cancer.",
"criterion": "prior chemotherapy for breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Patients must not have received prior ... hormonal therapy for the treatment of breast cancer.",
"criterion": "prior hormonal therapy for breast cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Karnofsky performance status of 70 or higher.",
"criterions": [
{
"exact_snippets": "Karnofsky performance status of 70 or higher",
"criterion": "Karnofsky performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 70,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Estimated life expectancy of at least 12 weeks.",
"criterions": [
{
"exact_snippets": "Estimated life expectancy of at least 12 weeks.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Adequate organ function including the following:",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "- Bone marrow: White blood cells (WBC) >= 3.5 x 109/L Absolute neutrophil (segmented and bands) count (ANC) >= 1.5 x 109/L Platelets >= 100 x 109/L Haemoglobin >= 9g/dL",
"criterions": [
{
"exact_snippets": "White blood cells (WBC) >= 3.5 x 109/L",
"criterion": "white blood cells (WBC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 3.5,
"unit": "x 109/L"
}
}
]
},
{
"exact_snippets": "Absolute neutrophil (segmented and bands) count (ANC) >= 1.5 x 109/L",
"criterion": "absolute neutrophil count (ANC)",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "x 109/L"
}
}
]
},
{
"exact_snippets": "Platelets >= 100 x 109/L",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "x 109/L"
}
}
]
},
{
"exact_snippets": "Haemoglobin >= 9g/dL",
"criterion": "haemoglobin",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9,
"unit": "g/dL"
}
}
]
}
]
},
{
"line": "- Hepatic: Bilirubin <= 1.5 x upper limit of normal (ULN), ALT or AST <= 2.5x ULN, (or <=5 X with liver metastases) Alkaline phosphatase <= 2.5x ULN.",
"criterions": [
{
"exact_snippets": "Bilirubin <= 1.5 x upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "ALT or AST <= 2.5x ULN",
"criterion": "ALT or AST level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "ALT or AST ... (or <=5 X with liver metastases)",
"criterion": "ALT or AST level with liver metastases",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "x ULN"
}
}
]
},
{
"exact_snippets": "Alkaline phosphatase <= 2.5x ULN",
"criterion": "alkaline phosphatase level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "- Renal: creatinine <= 1.5x ULN",
"criterions": [
{
"exact_snippets": "Renal: creatinine <= 1.5x ULN",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "x ULN"
}
}
]
}
]
},
{
"line": "* Cardiac:",
"criterions": [
{
"exact_snippets": "Cardiac",
"criterion": "cardiac condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate cardiac function",
"criterions": [
{
"exact_snippets": "Adequate cardiac function",
"criterion": "cardiac function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Signed informed consent from patient or legal representative.",
"criterions": [
{
"exact_snippets": "Signed informed consent from patient or legal representative.",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with reproductive potential must use an approved contraceptive method if appropriate (eg, intrauterine device, birth control pills, or barrier device) during and for three months after the study. Females with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.",
"criterions": [
{
"exact_snippets": "Patients with reproductive potential must use an approved contraceptive method",
"criterion": "reproductive potential",
"requirements": [
{
"requirement_type": "contraceptive use",
"expected_value": true
}
]
},
{
"exact_snippets": "Females with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "pregnancy test",
"expected_value": "negative"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Prior treatment for locally advanced or metastatic breast cancer.",
"criterions": [
{
"exact_snippets": "Prior treatment for locally advanced or metastatic breast cancer.",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "locally advanced or metastatic breast cancer"
}
]
}
]
},
{
"line": "* Treatment within the last 30 days with any investigational drug.",
"criterions": [
{
"exact_snippets": "Treatment within the last 30 days with any investigational drug.",
"criterion": "treatment with investigational drug",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.",
"criterions": [
{
"exact_snippets": "Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy",
"criterion": "concurrent cytotoxic chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Concurrent administration of any other tumor therapy, including ... hormonal therapy",
"criterion": "concurrent hormonal therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Concurrent administration of any other tumor therapy, including ... immunotherapy",
"criterion": "concurrent immunotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.",
"criterions": [
{
"exact_snippets": "Active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Pregnancy.",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Breast feeding.",
"criterions": [
{
"exact_snippets": "Breast feeding.",
"criterion": "breast feeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.",
"criterions": [
{
"exact_snippets": "Serious concomitant disorders",
"criterion": "serious concomitant disorders",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Poorly controlled diabetes mellitus.",
"criterions": [
{
"exact_snippets": "Poorly controlled diabetes mellitus",
"criterion": "diabetes mellitus",
"requirements": [
{
"requirement_type": "control",
"expected_value": "poorly controlled"
}
]
}
]
},
{
"line": "* Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.",
"criterions": [
{
"exact_snippets": "Second primary malignancy that is clinically detectable",
"criterion": "second primary malignancy",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": true
}
]
}
]
},
{
"line": "* Symptomatic brain metastasis.",
"criterions": [
{
"exact_snippets": "Symptomatic brain metastasis",
"criterion": "brain metastasis",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
}
]
}
]
},
{
"line": "* History of significant neurological or mental disorder, including seizures or dementia.",
"criterions": [
{
"exact_snippets": "History of significant neurological or mental disorder",
"criterion": "neurological or mental disorder",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "significance",
"expected_value": "significant"
}
]
},
{
"exact_snippets": "seizures",
"criterion": "seizures",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "dementia",
"criterion": "dementia",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Peripheral neuropathy of >= CTC grade 2.",
"criterions": [
{
"exact_snippets": "Peripheral neuropathy of >= CTC grade 2.",
"criterion": "peripheral neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "CTC grade"
}
}
]
}
]
},
{
"line": "* History of hypersensitivity to drugs formulated in Tween 80, the vehicle used for commercial docetaxel formulations.",
"criterions": [
{
"exact_snippets": "History of hypersensitivity to drugs formulated in Tween 80",
"criterion": "hypersensitivity to drugs formulated in Tween 80",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}